HSITF:OTO-Hadasit Bio Holdings Ltd (USD)

COMMON STOCK | Biotechnology | OTC Pink

Last Closing

USD 0.13

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Hadasit Bio Holdings Ltd operates as an investment holding company. The Company through it holdings is engaged in research and development in the medical and biotechnology fields.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 649.39B
CMXHF CSL Limited

N/A

USD 94.38B
CSLLY CSL Ltd

N/A

USD 92.66B
UCBJF UCB SA

N/A

USD 28.35B
UCBJY UCB SA ADR

N/A

USD 27.94B
ARGNF argenx SE

N/A

USD 23.04B
GNMSF Genmab A/S

N/A

USD 16.66B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.87B
REGMF RemeGen Co. Ltd

N/A

USD 6.81B
IVBIY IVBIY

N/A

USD 6.79B

ETFs Containing HSITF

XFI:CA 1.96 % 0.51 %

N/A

N/A
MEU:CA Mackenzie Maximum Diversi.. 1.43 % 0.61 %

N/A

CAD 6.92M
RODM Hartford Multifactor Deve.. 0.98 % 0.31 %

N/A

USD 1.11B
MVAE:LSE 0.77 % 0.00 %

N/A

N/A
MVEX:LSE 0.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.00% 24% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.00% 25% F 12% F
Trailing 12 Months  
Capital Gain 43,233.33% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 43,233.33% 100% F 100% F
Trailing 5 Years  
Capital Gain -89.76% 40% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.76% 40% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 934.27% 92% A 96% N/A
Dividend Return 934.27% 92% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6,330.24% 6% D- 4% F
Risk Adjusted Return 14.76% 66% D+ 49% F
Market Capitalization 0.07B 33% F 22% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector